Oramed Pharmaceuticals Inc

Research Oramed Pharmaceuticals Inc (ORMP) on Bullrun: valuation model: 280.5% undervalued, market cap USD 189.90M, P/E 1.8, dividend yield 5.4%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerORMP
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Valuation signal280.5% undervalued
• Market capUSD 189.90M
• P/E1.8
• Dividend yield5.4%
• Financial periodFY2025
• RevenueUSD 2.00M
• Net incomeUSD 64.05M
• Free cash flow-USD 9.15M
• Gross margin0.7%

Valuation Snapshot

Bullrun's latest valuation model marks Oramed Pharmaceuticals Inc as 280.5% undervalued; latest market cap is USD 189.90M; P/E is 1.8; dividend yield is 5.4%.

About Oramed Pharmaceuticals Inc

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.

Frequently asked questions

Is Oramed Pharmaceuticals Inc overvalued or undervalued?

Bullrun's valuation model currently marks Oramed Pharmaceuticals Inc as 280.5% undervalued.

What is Oramed Pharmaceuticals Inc's market cap?

Oramed Pharmaceuticals Inc's market capitalization is USD 189.90M.

What is Oramed Pharmaceuticals Inc's P/E ratio?

Oramed Pharmaceuticals Inc's price-to-earnings (P/E) ratio is 1.8.

Does Oramed Pharmaceuticals Inc pay a dividend?

Oramed Pharmaceuticals Inc has a dividend yield of 5.4%.

What does Oramed Pharmaceuticals Inc do?

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.